Microscopic colitis is a common cause of chronic watery diarrhea among the elderly. Although the prevalence of celiac disease appears to be higher in patients with microscopic colitis, the relationship between dietary gluten intake and risk of microscopic colitis among individuals without celiac disease has not been explored.
INTRODUCTION
Microscopic colitis is a common cause of chronic watery diarrhea characterized by lymphocytic infiltration of colonic mucosa with or without expansion of collagen fiber in the lamina propria (1) . The cause of microscopic colitis is largely unknown, but may be due to an inappropriate immune response to the gut luminal microenvironment in genetically susceptible individuals (2) . The disease has emerged as a common cause of non-bloody diarrhea in the past decade with recent data suggesting that up to 10 to 20% of patients with chronic diarrhea are diagnosed with microscopic colitis (3) . Microscopic colitis and celiac disease share many clinical manifestations with a number of studies demonstrating a higher prevalence (4-15%) of celiac disease among patients with lymphocytic subtype of microscopic colitis (4) (5) (6) . Previous reports have suggested that some patients with concomitant celiac disease may have improvements in disease activity following a gluten-free diet, minimizing the need for medical therapy (6) . Nevertheless, the role of gluten, the dietary antigen in celiac disease, in the pathogenesis of microscopic colitis remains largely unknown.
Recently, gluten has been implicated in the etiology of a wide range of conditions, encompassing metabolic syndrome, neurologic disorders, and cardiovascular diseases (7) . The increasing concern about dietary gluten intake both in the medical community and lay public has resulted in the reduction or avoidance of gluten intake by segments of the general population without celiac disease, particularly among individuals with chronic gastrointestinal disorders (8) . In microscopic colitis, where the bestestablished treatment is corticosteroids, patients may opt to adhere to a gluten-free diet for its perceived safety and benefits in relieving intestinal symptoms. On the other hand, gluten avoidance may, at least in part, be associated with less healthy eating pattern through reduction in consumption of whole grains. As such, systematic evaluation of the role of gluten in chronic gastrointestinal disorders may have a significant role in informing public health recommendations regarding intake of gluten (8) . We therefore sought to examine the association between dietary gluten intake and risk of incident microscopic colitis in two large prospective cohorts of US women, the Nurses' Health Study (NHS) and NHSII. With over 20 years of validated and updated data on lifestyle and dietary information, these cohorts offer a unique opportunity to examine the relationship between dietary gluten intake and risk of microscopic colitis.
METHODS

Study population
The prospective NHS began in 1976 when 121,530 female nurses, aged 30 to 55 years, residing in eleven US states provided detailed information on their lifestyle and medical history. Similarly, NHSII was established in 1989 when 116,533 female nurses, aged 25 to 42 years, provided information on lifestyle, reproductive factors, and medical diagnoses. In both cohorts, participants have been followed biennially by self-administered questionnaires on lifestyle factors, anthropometric measurements, medications, and medical conditions until 2014 in NHS and 2015 in NHSII. The overall follow-up rate is above 90% for NHS and above 85% for NHSII (9) . The study was approved by the institutional review boards of both the Brigham and Women's Hospital and the Harvard T.H. Chan School of Public Health.
We excluded participants who reported a diagnosis of celiac disease at any time during the study period. Among eligible participants who completed a semi-quantitative food frequency questionnaire (SFFQ) at baseline (1986 in NHS and 1991 in NHSII, n 5 167,026), we additionally excluded participants with pre-existing inflammatory bowel disease, microscopic colitis, cancer, or missing body weight (n56282, Fig. 1 ). As shown previously, the baseline characteristics of participants who completed SFFQ were similar to those of the entire cohort (10). 
Ascertainment of microscopic colitis
In both cohorts, a diagnosis of microscopic colitis was selfreported initially and was subsequently confirmed by two gastroenterologists (KEB and HK) (11) . Since 1976 in NHS and 1989 in NHSII, participants reported diagnoses of inflammatory bowel diseases, including microscopic colitis, ulcerative colitis, and Crohn's disease during biennial questionnaires. When a diagnosis of microscopic colitis was reported, participants were sent supplementary questionnaires and requests to obtain relevant medical records. We collected data on diagnostic tests, endoscopy results, histopathology, and laboratory findings. Confirmation of cases was based on histopathology records review by two independent gastroenterologists blinded to exposure information. When possible, we also obtained information on microscopic colitis subtypes (lymphocytic colitis and collagenous colitis). We excluded participants who subsequently denied microscopic colitis on the supplementary questionnaires, participants who did not give permission to review their medical records, and participants whose diagnoses of microscopic colitis were not confirmed after review of medical records.
Assessment of gluten intake
In NHS, dietary intake was assessed by validated SFFQ every 4 years since 1986 (12) . In NHSII, a similar SFFQ was administered every 4 years since 1991. The SFFQ evaluated the habitual frequency of consumption of various food items in standard portion sizes during the previous year. Available responses ranged from "never or less than once per month" to "6 or more times per day." We derived individual dietary components based on the Harvard Food Composition Database (13) .
Measurements of dietary gluten intake had been reported in detail previously (8) . Briefly, the quantity of dietary gluten intake was calculated based on the protein content of wheat, rye, and barley within each food item. Consistent with previous studies, we used the more conservative estimate of conversion factor of 75% when calculating the proportion of protein content that comprised gluten to avoid overestimating the intakes (14) . We did not include trace sources of gluten (for example, gluten from oats and condiments) as the quantity is likely to have been trivial compared to that from grains and cereals (15) . The SFFQ method of measuring plant-derived protein (mainly gluten) has previously been demonstrated to correlate reasonably with measurements by 7-day dietary records (Spearman correlation coefficient 0.66) (16) . Additionally, in two recent validation studies nested in NHSII (n 5 732) and the parallel Health Professionals Follow-Up Study (n 5 650), the energy-adjusted Spearman rank correlation coefficient (95% CI) comparing gluten intake from the second SFFQ with average of both 7-day dietary records were 0.55 (0.48-0.61) and 0.58 (0.52-0.64), respectively, confirming the validity of SFFQ in measuring dietary gluten intake.
We obtained energy-adjusted gluten intake using the residual method, which allowed us to focus on the nutrient component independent of total energy intake and reduce effects of over and under reporting by participants (17) . To reduce measurement errors and to represent long-term dietary patterns, we used the cumulative average of energy-adjusted gluten intake as our main exposure (18) . As an example, we calculated the cumulativeaverage gluten intake in 1999 as the average of daily gluten consumption reported in 1991, 1995, and 1999. We also performed a sensitivity analysis using simple-updated energyadjusted gluten intake (using the most recent SFFQ) to focus on the influence of more recent, short-term gluten intake on disease risk. For example, estimated gluten intake from the 1999 SFFQ was used for follow-up cycle from 1999 to 2001. Finally, to minimize the possibility that subclinical or undiagnosed microscopic colitis may influence intake of gluten, we also introduced a 4-year lag in our sensitivity analyses where energy-adjusted gluten intake was derived from a SFFQ at least 4 years prior to each follow-up cycle.
Assessment of covariates
In both cohorts, height was recorded at baseline when cohorts were initiated (1976 in NHS and 1989 in NHSII). Body weight was updated every 2 years via questionnaires. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared (kg/m 2 ). Assessment of smoking status has been reported in detail previously (19, 20) . Participants provided their past smoking habits, including the age at which they started or stopped smoking, during the baseline questionnaire. Current smoking status and the number of cigarettes smoked daily were updated in the biennial questionnaires. We categorized smoking status as never, past, and current. Participants who smoked less than 20 cigarettes in their lifetime were categorized as never-smokers.
Physical activity was self-reported using a validated questionnaire on average every four years (21) . Participants were asked to provide the average time per week spent in recreational activities (for example, walking, jogging, or bicycling) during the past year. A metabolic equivalent of tasks (MET) score was assigned to each physical activity based on energy expenditure (22) . We calculated the amount of physical activity by multiplying the average time spent in each activity by the MET score. We also assessed diet quality using the Alternative Healthy Eating Index (AHEI) score, which was constructed based on dietary factors that have been consistently associated with a lower risk of chronic diseases (23) . Menopausal status and the use of menopausal hormones were also evaluated using biennial questionnaires. In a subset of NHS participants, the reproducibility of self-reported menopausal status was .98% between questionnaire cycles (24) . Finally, starting from 1989 in NHSII and 1990 in NHS, we asked information on current regular use (at least twice weekly) of nonsteroid anti-inflammatory drugs (NSAIDs). Similarly, we have inquired information about regular use of proton pump inhibitors (PPIs) since 2000 in NHS and 2001 in NHSII and regular use of anti-depressants (e.g., selective serotonin reuptake inhibitors (SSRIs) etc.) since 1996 in NHS and 1993 in NHSII. As these medications have previously been associated with risk of microscopic colitis (25, 26) , we performed secondary analysis limiting the study period to 2000-2014 in NHS and 2001-2015 in NHSII to account for the use of these medications in our models.
Statistical analysis
Person time was calculated from the date of return of baseline questionnaire (1986 in NHS and 1991 in NHSII) to the date of diagnosis of microscopic colitis, death from any cause, last returned questionnaire, or end of follow up (2014 in NHS and 2015 in NHSII), whichever came first. We modeled gluten intake as quintiles of cumulative-average intake updated every 4 years. We estimated age-adjusted and multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) using Cox proportional hazard modeling stratified by age (in months) and study period (2-year intervals). Models were adjusted for the following variables, chosen a priori: age, smoking status, menopausal hormone therapy, AHEI score (in quintiles), physical activities (quintiles), current regular use of NSAIDs (yes/no), and BMI (,25 kg/m 2 , 25-29.9 kg/m 2 , and $30 kg/m 2 ). All covariates, including dietary gluten intake, were assessed as time-varying exposures. Test of linear trend was performed by analyzing dietary gluten intake as a continuous variable. We examined whether the association between gluten intake and risk of microscopic colitis differed according to disease subtype using the log likelihood ratio test to compare model fit between models assuming a common effect and models allowing separate associations across collagenous and lymphocytic colitis subtypes (27) .
In exploratory analyses, we evaluated the relationship between dietary gluten intake and risk of microscopic colitis according to strata defined by age (,60 vs. $60 years), BMI (,25 vs. $25 kg/ m 2 ), and smoking (never vs. ever). We tested for effect modification by comparing models with cross-classified categories of gluten and each stratum with those with main effects only using log likelihood ratio tests. All statistical analyses were conducted with SAS version 9.4 (SAS Institute, Cary, NC). Significance was set as a P value , 0.05 in a two-tailed test.
RESULTS
After exclusion, a total of 160,744 participants were eligible for our study, which included 67,836 women in NHS and 92,908 women in NHSII. Table 1 demonstrates the baseline characteristics of participants according to quintiles of gluten intake. On average, participants in the highest quintile of gluten intake consumed more whole grains and refined grains and were more likely to be never-smokers. In contrast, there did not appear to be any differences in age, BMI, physical activity, and menopausal status according to quintiles of gluten intake.
Through 2014 in NHS and 2015 in NHSII, we documented 219 incident cases of microscopic colitis over 3,716,718 personyears of follow up. Of the 219 patients with microscopic colitis, we were able to confirm 105 cases of collagenous and 103 cases of lymphocytic colitis. The remaining 11 cases had histopathology reports of either a diagnosis of "microscopic colitis" only or did not provide sufficient information about collagen band thickness.
Dietary gluten intake was not associated with risk of microscopic colitis (P trend 5 0.88, Table 2 ). Compared to women in the lowest quintile of energy-adjusted gluten intake, the multivariableadjusted HRs for microscopic colitis were 1.18 (95% CI: 0.77-1.78) for women in the middle quintile and 1.03 (95% CI: 0.67-1.58) for women in the highest quintile of gluten intake. The associations remained non-significant when we additionally adjusted for the primary sources of gluten. When additionally adjusted for refined grains, the multivariable-adjusted HRs were 1.24 (95% CI: 0.79-1.94) for the middle quintile and 1.15 (95% CI: 0.67-1.99) for the highest quintile of gluten intake (P trend 5 0.69). When additionally adjusted for whole grains intake, the multivariable-adjusted HRs were 1.16 (95% CI: 0.76-1.76) for women in the middle quintile and 0.99 (95% CI: 0.63-1.56) for women in the highest quintile of dietary gluten intake (P trend 5 0.93). We also repeated these analyses using deciles of cumulative intake of gluten and observed similar results. Compared to individuals in the lowest decile of cumulative-average intake of The American Journal of GASTROENTEROLOGY VOLUME 114 | JANUARY 2019 www.amjgastro.com gluten (average gluten intake 5 3.1 6 0.7 g), the multivariableadjusted HR for the highest decile (average gluten intake 5 9.1 6 1.5 g) was 0.94, 95% CI: 0.50-1.78. In our secondary analysis restricting our follow-up period to after 2000 in NHS and 2001 in NHSII to account for the use of SSRIs and PPIs, we found no association between dietary gluten intake and risk of microscopic colitis (P trend 5 0.67).
We also examined the influence of more recent short-term intake of gluten on risk of microscopic colitis and observed similar results (P trend 5 0.41). Compared to participants in the lowest quintile of simple-updated dietary gluten intake, the multivariable-adjusted HR of microscopic among those in the highest quintile was 0.91, 95% CI: 0.58-1.44. Finally, we considered the possibility that undiagnosed or subclinical symptoms of microscopic colitis may influence intake of gluten intake and therefore performed a 4-year lagged analysis to account for the possibility of reverse causation. Similar to our primary analyses, we did not observe an association between dietary gluten intake and risk of microscopic colitis (P trend 5 0.70). Compared to the participants in the lowest quintile of dietary gluten intake, the multivariable-adjusted HR of microscopic among those in the highest quintile was 1.25, 95% CI: 0.81-1.95.
We explored the relationship between dietary gluten intake and risk of microscopic colitis according to disease subtypes ( Table 3 ). The association between gluten intake and risk of microscopic colitis did not differ according to disease subtypes (P heterogeneity 5 0.72). For women in the highest quintile of gluten intake, the multivariable-adjusted HR for collagenous colitis was 1.05 (95% CI: 0.54-2.03) compared to women in the lowest quintile of gluten intake. Similarly, for women in the highest quintile of gluten intake, the multivariable-adjusted HR for lymphocytic colitis was 1.04 (95% CI: 0.58-1.86) compared to women in the lowest quintile of gluten intake.
Finally, we examined the association between gluten intake and risk of microscopic colitis according to strata defined by age, BMI, and smoking (Table 4 ) and did not observe any evidence for effect modification (all P interaction $ 0.17). 
DISCUSSION
In two large prospective cohort studies of US women, we found no association between dietary gluten intake and risk of microscopic colitis among patients without celiac disease. The results were consistent in multiple sensitivity analyses, across different subtypes of microscopic colitis and subgroups defined by age, BMI, and smoking status. The exact mechanism by which microscopic colitis develops genome wide association study demonstrating variants within remains largely uncharacterized (1,2) . Nevertheless, the pres-HLA gene to be associated with risk of collagenous colitis, indicate ence of marked female preponderance and findings from a recent an immune-mediated etiology (28, 29) . Studies of environmental risk factors for microscopic colitis have largely focused on medications, with NSAIDs and proton pump inhibitors previously been associated with increased risk (30, 31) . Celiac disease, in addition to being more prevalent among patients with microscopic colitis, also has histologic characteristics that are remarkably similar to that of microscopic colitis, particularly the lymphocytic colitis subtype (5). Therefore, it is possible that gluten may represent a common luminal antigen for both disorders. This hypothesis is further supported by the previous observation that a gluten enema can induce lymphocytic colitis-like changes in patients with celiac disease (32) . A number of case studies have shown that among patients with co-existing microscopic colitis and celiac disease, both diseases may respond to a gluten-free diet (1, 6, 33) . Despite these lines of evidence, we did not observe an association between gluten intake and risk of microscopic colitis among individuals without celiac disease. Additionally, we evaluated this association in the context of the primary sources of gluten intake namely refined and whole grains and observed no significant changes in our effect estimates, suggesting that regardless of the source, gluten is not associated with risk of microscopic colitis. These results are particularly relevant at a time when a low gluten diet or gluten-free diet are gaining popularity in the general population especially in patients with chronic intestinal symptoms (34, 35) .
To the best of our knowledge, no prior study has examined the role of gluten-free diet in treatment of microscopic colitis. Nevertheless, our data suggest that the pathogenesis of microscopic colitis, at least in patients without celiac disease, is likely not related to gluten consumption and therefore in contrast to celiac disease, it is unlikely that gluten withdrawal would lead to improvement in histologic inflammation or clinical symptoms. This hypothesis is supported by earlier work from Freeman who demonstrated that large consumption of dietary gluten for over one month in two patients with established lymphocytic colitis was not associated with any histologic changes in the proximal small intestine or changes in severity of inflammation in the colon (36) . Interestingly, even in a large series of patients with established celiac disease (n 5 1009), the majority of cases of microscopic colitis occurred after the diagnosis of celiac disease while patients were already on gluten-free diet with no clear correlations in changes in duodenal and colonic biopsies following dietary changes, indicating that even in patients with celiac disease, adherence to a gluten-free diet may not alter the development or progression of microscopic colitis (6) . Nevertheless, we acknowledge that similar to inflammatory bowel disease, microscopic colitis may also represent a heterogeneous group of disorders and therefore whether gluten intake can play a role in a subgroup of cases with specific genetic susceptibility cannot be entirely ruled out.
The strengths of our study include large, well-established cohorts with high response rates and over 20 years of follow up. The repeated assessments of lifestyle, diet, medications, and outcome data over time allowed us to account for changes in the distribution of confounders during the study period and reduced the possibility of recall bias. The detailed and validated information on diet also minimized measurement errors. Finally, with diagnosis confirmation by medical records review, we were able to distinguish whether the associations varied according to disease subtype.
Our study has several limitations that are worth noting. First, our study comprised mainly Caucasian women. While this may influence the generalizability of our findings, previous studies suggested that the risk of microscopic colitis is much higher among women with a female-to-male gender ratio up to 9:1 (37, 38) . The all-female composition makes our cohorts particularly suitable to study risk factors for the disease. Specifically, we estimated that our study had over 80% power to detect a HR of at least 1.8 comparing individuals in the highest quintiles of gluten intake to those in the lowest quintile. Nevertheless, in our cohort and consistent with prior studies (11, 30, 31) , use of NSAIDs (HR 5 2.78, 95% CI 1.69-4.59), SSRIs (HR 5 1.87, 95% CI 1.33-2.61), and smoking (HR 5 2.52 (95% CI, 1.59-4.00) are strongly associated with risk of microscopic colitis, indicating that the contribution of gluten to the risk of microscopic colitis, if any, is minimal. Third, this study relied on self-reported questionnaires for assessing dietary gluten intake which may be subject to measurement errors. However, our validation studies have demonstrated strong correlation between gluten intake derived from SFFQ to that of diet records. Nevertheless, we were unable to directly identify participants who were on a gluten-free diet and cannot examine whether such diet is protective against the development of microscopic colitis. Fourth, data on diagnosis of microscopic colitis was initially reported by the participants which may have led to under-ascertainment of the outcome. However, as previously demonstrated the incidence rates of microscopic colitis in our cohorts are similar to those of other population-based cohorts and our participants are nurses with high health literacy increasing the likelihood of reporting the diagnosis (11). The slightly lower overall incidence rate compared to some of the prior studies is largely due to the younger age of our participants relative to the peak age of diagnosis. Finally, the observational nature of our cohorts prevents us from excluding residual confounding. However, we were able to adjust for a variety of established risk factors for microscopic colitis, including smoking and NSAIDs use using prospectively collected data and adjustment for these factors did not materially alter our effect estimates (11, 38) .
CONCLUSION
In summary, we found no association between dietary gluten intake during adulthood and risk of microscopic colitis in two large, prospective cohorts of US women without celiac disease. Together with prior studies, these data provide compelling evidence that microscopic colitis is largely not a gluten-induced disorder.
